The ornithology of Illinois. Part I. Descriptive catalogue. By Robert Ridgway. Part II. Economic ornithology. By S. A. Forbes. Pub. by the authority of the state Legislature.

v.1 pt.1

The ornithology of Illinois. Part I. Descriptive catalogue. By Robert Ridgway. Part II. Economic ornithology. By S. A. Forbes. Pub. by the authority of the state Legislature.

v.2 pt.1

Amphipoda I. Gammaridea, by the Rev. T. R. R. Stebbing ...

21

Implementation of the I.S. EN 16001:2009 energy management standard into GlaxoSmithKline (GSK) Ltd, Cork

As manufacturers face an increasingly competitive environment, they seek out opportunities to reduce production costs without negatively affecting the yield or the quality of their finished products. The challenge of maintaining high product quality while simultaneously reducing production costs can often be met through investments in energy efficient technologies and energy efficiency practices. Energy management systems can offer both technological and best practice efficiencies in order to achieve substantial savings. A strong energy management system provides a solid foundation for an organisation to reduce production costs and improve site efficiency. The I.S EN16001 energy management standard specifies the requirements for establishing, implementing, maintaining and improving an energy management system and represents the latest best practice for energy management in Ireland. The objective of the energy management system is to establish a systematic approach for improving energy performance continuously. The I.S EN16001 standard specifies the requirements for continuous improvement through using energy more efficiently. The author analysed how GlaxoSmithKline’s (GSK) pharmaceutical manufacturing facility in Cork implemented the I.S. EN16001 energy management system model, and defined how energy saving opportunities where identified and introduced to improve efficiency performance. The author performed an extensive literature research in order to determine the current status of the pharmaceutical industry in Ireland, the processes involved in pharmaceutical manufacturing, the energy users required for pharmaceutical manufacturing and the efficiency measures that can be applied to these energy users in order to reduce energy consumption. The author then analysed how energy management standards are introduced to industry and critically analysed the driving factors for energy management performance in Ireland through case studies. Following an investigation as to how the I.S. EN16001 energy management standard is operated in GSK, a critical analysis of the performance achieved by the GSK energy management system is undertaken in order to determine if implementing the I.S EN16001 standard accelerates achieving energy savings. Since its introduction, the I.S. EN16001 model for energy management has enabled GSK to monitor, target and identify energy efficiency opportunities throughout the site. The model has put in place an energy management system that is continuously reviewed for improvement and to date has reduced GSK’s site operations cost by over 30% through technical improvements and generating energy awareness for smarter energy consumption within the GSK Cork site. Investment in I.S. EN16001 has proved to be a sound business strategy for GSK especially in today's manufacturing environment.

Report of the United States Geological Survey of the territories. F.V. Hayden, United States geologist in charge ... [Final reports or monographs. vol. I]-III, V-XIII.

7

ძველი საქართველო. ტომი I

„საქართველოს საისტორიო და საეთნოგრაფიო საზოგადოების“ მიერ გამოცემულია კრებული „ძველი საქართველო“, რომელშიც მოთავსებულია როგორც რეფერატები და გამოკვლევები, ისე ყოველგვარი მასალა საქართველოს ეთნოგრაფიის და წარსულის შესახებ. პირველი ტომი შეიცავს ექვს განყოფილებას. პირველ განყოფილებაში მოთავსებულია ნეკროლოგები ალექსანდრე ეპისკოპოსისა, ნიკოლოზ ხიზანიშვილისა და ალექსანდრე ჭყონიასი; მეორეში - რეფერატები, რომლებიც წაკითხული იყო საზოგადოების კრებაზე; მესამეში საისტორიო და სალიტერატურო მასალანი; მეოთხეში სახალხო სიტყვიერება; მეხუთეში ხალხური სიმღერები ნოტებზე გადატანილი და მეექვსეში საზოგადოების კრებათა ოქმები და წევრთა სია.

Algæ. Vol. I. Myxophyceæ, Peridinieæ, Bacillarieæ, Chlorophyceæ, together with a brief summary of the occurrence and distribution of freshwat4er Algæ. By G.S. West.

v.1 (1916)

Algæ. Vol. I. Myxophyceæ, Peridinieæ, Bacillarieæ, Chlorophyceæ, together with a brief summary of the occurrence and distribution of freshwat4er Algæ. By G.S. West.

v.1 (1916)

Comparação entre troponina I cardíaca e CK-MB massa em síndrome coronariana aguda sem supra de ST

FUNDAMENTO: Há incertezas do valor prognóstico comparativo entre troponina I cardíaca (cTnI) e CK-MB em síndrome coronariana aguda (SCA). OBJETIVO: Comparar o valor prognóstico entre a cTnI e a CK-MB massa em pacientes com SCA sem supradesnível do segmento ST. MÉTODOS: Foram analisados 1.027 pacientes, de modo prospectivo, em um centro terciário de cardiologia. Combinações dos biomarcadores foram examinadas: cTnI normal, CK-MB massa normal (65,5%); cTnI normal, CK-MB massa elevada (3,9%); cTnI elevada, CK-MB massa normal (8,8%); cTnI elevada, CK-MB massa elevada (20,7%). Análise multivariada de variáveis clínicas, eletrocardiográficas e laboratoriais determinou o valor prognóstico independente dos biomarcadores para o evento de morte ou (re)infarto em 30 dias. RESULTADOS: Pacientes com pelo menos um biomarcador elevado foram mais idosos (p = 0,02) e do sexo masculino (p < 0,001). Uso prévio de aspirina (p = 0,001), betabloqueador (p = 0,003) ou estatina (p = 0,013) foi mais frequente naqueles sem elevação da cTnI. Pacientes com elevação de ambos os biomarcadores tinham mais depressão do segmento ST (p < 0,001) ou creatinina elevada (p < 0,001). Em análise multivariada com a inclusão da cTnI, a CK-MB massa não foi variável independente para o evento de morte ou (re)infarto em 30 dias (odds ratio [OR] 1,16; p = 0,71). Quando não se incluiu a cTnI, teve-se: idade (OR 1,07; p < 0,001); sexo masculino (OR 1,09; p = 0,77); diabete melito (OR 1,95; p = 0,02); acidente vascular cerebral prévio (OR 3,21; p = 0,008); creatinina elevada (OR 1,63; p = 0,002); elevação da CK-MB massa (OR 1,96; p = 0,03); estatística-C 0,77 (p < 0,001). CONCLUSÃO: Com dosagem da cTnI, a CK-MB massa pode ser dispensável para avaliação prognóstica. Na indisponibilidade da cTnI, a CK-MB massa é aceitável para decisão terapêutica.